Literature DB >> 22127558

Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide.

Yasuyoshi Morita, Takahiro Shimada, Terufumi Yamaguchi, Shinya Rai, Chikara Hirase, Masakatsu Emoto, Kentaro Serizawa, Yasuhiro Taniguchi, Mayuko Ojima, Yoichi Tatsumi, Takashi Ashida, Itaru Matsumura.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22127558     DOI： 10.1007/s12185-011-0973-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  5 in total

1.  Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma.

Authors:  Shuji Ozaki; Takeshi Harada; Shiro Fujii; Shingen Nakamura; Hirokazu Miki; Ayako Nakano; Kumiko Kagawa; Kyoko Takeuchi; Masahiro Abe; Toshio Matsumoto
Journal:  Int J Hematol       Date:  2011-02-01       Impact factor: 2.490

Review 2.  Immunomodulatory drugs in multiple myeloma.

Authors:  Maurizio Zangari; Francesca Elice; Guido Tricot
Journal:  Expert Opin Investig Drugs       Date:  2005-11       Impact factor: 6.206

3.  Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Authors:  Paul G Richardson; Robert L Schlossman; Edie Weller; Teru Hideshima; Constantine Mitsiades; Faith Davies; Richard LeBlanc; Laurence P Catley; Deborah Doss; Kathleen Kelly; Mary McKenney; Julie Mechlowicz; Andrea Freeman; Reggie Deocampo; Rebecca Rich; Joan J Ryoo; Dharminder Chauhan; Kathe Balinski; Jerome Zeldis; Kenneth C Anderson
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

Review 4.  Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Authors:  H Quach; D Ritchie; A K Stewart; P Neeson; S Harrison; M J Smyth; H M Prince
Journal:  Leukemia       Date:  2009-11-12       Impact factor: 11.528

5.  Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.

Authors:  K Dredge; J B Marriott; C D Macdonald; H-W Man; R Chen; G W Muller; D Stirling; A G Dalgleish
Journal:  Br J Cancer       Date:  2002-11-04       Impact factor: 7.640
  5 in total
  1 in total

1.  Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma.

Authors:  Takeshi Harada; Shuji Ozaki; Asuka Oda; Shiro Fujii; Shingen Nakamura; Hirokazu Miki; Kumiko Kagawa; Kyoko Takeuchi; Toshio Matsumoto; Masahiro Abe
Journal:  Int J Hematol       Date:  2013-04-23       Impact factor: 2.490
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.